Polypharmacy among older adults with dementia compared with those without dementia in the United States
- PMID: 34101822
- PMCID: PMC8440349
- DOI: 10.1111/jgs.17291
Polypharmacy among older adults with dementia compared with those without dementia in the United States
Abstract
Background/objectives: In older persons with dementia (PWD), extensive medication use is often unnecessary, discordant with goals of care, and possibly harmful. The objective of this study was to determine the prevalence and medication constituents of polypharmacy among older PWD attending outpatient visits in the United States.
Design: Cross-sectional analysis.
Setting and participants: PWD and persons without dementia (PWOD) aged ≥65 years attending outpatient visits recorded in the nationally representative National Ambulatory Medical Care Survey (NAMCS), 2014-2016.
Measurements: PWD were identified as those with a diagnosis of dementia on the NAMCS encounter form and/or those receiving an anti-dementia medication. Visits with PWD and PWOD were compared in terms of sociodemographic, practice/physician factors, comorbidities, and prescribing outcomes. Regression analyses examined the effect of dementia diagnosis on contributions by clinically relevant medication categories to polypharmacy (defined as being prescribed ≥5 prescription and/or nonprescription medications).
Results: The unweighted sample involved 918 visits for PWD and 26,543 visits for PWOD, representing 29.0 and 780 million outpatient visits. PWD had a median age of 81 and on average had 2.8 comorbidities other than dementia; 63% were female. The median number of medications in PWD was eight compared with three in PWOD (p < 0.001). After adjustment, PWD had significantly higher odds of being prescribed ≥5 medications (AOR 3.0; 95% CI: 2.1-4.3) or ≥10 medications (AOR 2.8; 95% CI: 2.0-4.2) compared with PWOD. The largest sources of medications among PWD were cardiovascular and central nervous system medications; usage from other categories was generally elevated in PWD compared with PWOD. PWD had higher odds of receiving at least one highly sedating or anticholinergic medication (AOR 2.5; 95% CI: 1.6-3.9).
Conclusion: In a representative sample of outpatient visits, polypharmacy was extremely common among PWD, driven by a wide array of medication categories. Addressing polypharmacy in PWD will require cross-cutting and multidisciplinary approaches.
Keywords: dementia; outpatient care; polypharmacy; prescribing.
© 2021 The American Geriatrics Society.
Conflict of interest statement
Figures
Similar articles
-
Medication misuse and overuse in community-dwelling persons with dementia.J Am Geriatr Soc. 2023 Oct;71(10):3086-3098. doi: 10.1111/jgs.18463. Epub 2023 Jun 5. J Am Geriatr Soc. 2023. PMID: 37272899 Free PMC article.
-
Attitudes toward deprescribing among older adults with dementia in the United States.J Am Geriatr Soc. 2022 Jun;70(6):1764-1773. doi: 10.1111/jgs.17730. Epub 2022 Mar 10. J Am Geriatr Soc. 2022. PMID: 35266141 Free PMC article.
-
Physician and patient factors associated with the prescribing of medications for sleep difficulties that are associated with high abuse potential or are expensive: an analysis of data from the National Ambulatory Medical Care Survey for 1996-2001.Clin Ther. 2005 Dec;27(12):1970-9. doi: 10.1016/j.clinthera.2005.12.008. Clin Ther. 2005. PMID: 16507384
-
Factors associated with polypharmacy and the prescription of multiple medications among persons living with HIV (PLWH) compared to non-PLWH.AIDS Care. 2015;27(12):1443-8. doi: 10.1080/09540121.2015.1109583. Epub 2015 Nov 26. AIDS Care. 2015. PMID: 26608408
-
Lung cancer, comorbidities, and medication: the infernal trio.Front Pharmacol. 2024 Feb 21;14:1016976. doi: 10.3389/fphar.2023.1016976. eCollection 2023. Front Pharmacol. 2024. PMID: 38450055 Free PMC article. Review.
Cited by
-
Highly prevalent geriatric medications and their effect on β-amyloid fibril formation.BMC Neurol. 2024 Nov 14;24(1):445. doi: 10.1186/s12883-024-03930-7. BMC Neurol. 2024. PMID: 39543530
-
Patients with dementia: prevalence and type of drug-drug interactions.Front Pharmacol. 2024 Oct 28;15:1472932. doi: 10.3389/fphar.2024.1472932. eCollection 2024. Front Pharmacol. 2024. PMID: 39529888 Free PMC article.
-
Association between Polypharmacy and Adverse Events in Patients with Alzheimer's Disease: An Analysis of the Japanese Adverse Drug Event Report Database (JADER).Medicina (Kaunas). 2024 Oct 6;60(10):1633. doi: 10.3390/medicina60101633. Medicina (Kaunas). 2024. PMID: 39459419 Free PMC article.
-
Efficacy of therapeutic intervention with NanoBEO to manage agitation and pain in patients suffering from severe dementia: a pilot clinical trial.Front Pharmacol. 2024 Aug 1;15:1417851. doi: 10.3389/fphar.2024.1417851. eCollection 2024. Front Pharmacol. 2024. PMID: 39148533 Free PMC article.
-
Use of Potentially Inappropriate Medications among Older Adults with Dementia or Cognitive Impairment Attending Memory Clinics: A Protocol for a Systematic Review and Meta-Analysis.Biomed Hub. 2024 May 22;9(1):83-88. doi: 10.1159/000539074. eCollection 2024 Jan-Dec. Biomed Hub. 2024. PMID: 39015200 Free PMC article.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
